14 terminated. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Terminated 14 |
| Phase 2 | 4 | Terminated 4 |
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers Niraparib, Dostarlimab, Short course radiation - Rectal Neoplasms, Rectal Neoplasm Malignant | Phase 1 | Terminated | University of Iowa | 3 | 2022-07-07 | 2026-06-29 |
| CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients Cohort 1: Dose Escalation, Cohort 2: Dose Escalation - Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer | Phase 1 | Terminated | University of Alabama at Birmingham | 1 | 2021-09-01 | 2023-11-21 |
| Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors RP-3500 (camonsertib) - Advanced Solid Tumor, Adult | Phase 1 / Phase 2 | Terminated | Repare Therapeutics | 156 | 2021-07-21 | 2025-10-30 |
| Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) Niraparib (Tablet for oral suspension), Dostarlimab, Niraparib (Tablet) - Neoplasms | Phase 1 | Terminated | GlaxoSmithKline | 47 | 2020-10-06 | 2026-01-21 |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months AsiDNA, Niraparib, Olaparib - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 13 | 2020-10-05 | 2024-12-05 |
| ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Elimusertib (BAY1895344), Niraparib - Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer | Phase 1 | Terminated | Bayer | 14 | 2020-02-26 | 2023-12-21 |
| Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix Nirapaib - Metastatic Carcinoma of the Cervix | Phase 1 / Phase 2 | Terminated | Michelle S Ludwig | 4 | 2019-07-15 | 2024-09-03 |
| Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Niraparib, Osimertinib - Lung Cancer | Phase 1 | Terminated | Massachusetts General Hospital | 20 | 2019-06-06 | 2026-09-21 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) Atezolizumab, Enfortumab Vedotin, Niraparib - Urothelial Carcinoma, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 272 | 2019-06-01 | 2026-08-03 |
| Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Niraparib, Carboplatin - Solid Tumor, Adult, Homologous Recombination Deficiency | Phase 1 | Terminated | Georgetown University | 23 | 2017-10-13 | 2024-02-05 |
| Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) Enzalutamide, Niraparib - Metastatic Prostate Cancer | Phase 1 | Terminated | Paul Mathew, MD | 2 | 2016-03-01 | 2019-10-21 |
| MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) MK-4827 + pegylated liposomal doxorubicin - Ovarian Cancer | Phase 1 | Terminated | Tesaro, Inc. | 6 | 2010-11-01 | 2016-10-19 |
| A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) MK-4827 - Neoplasms, Solid Tumors | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 3 | 2010-11-01 | 2012-06-28 |
| A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) MK-4827, carboplatin, paclitaxel - Cancer: Solid Tumors | Phase 1 | Terminated | Tesaro, Inc. | 12 | 2010-07-01 | 2016-05-05 |
Ovarian Neoplasms (4) · Neoplasms (3) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Neuroblastoma (1) · Osteosarcoma (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Tesaro, Inc. (2) · Bayer (1) · Georgetown University (1) · GlaxoSmithKline (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Massachusetts General Hospital (1) · Merck Sharp & Dohme LLC (1) · Michelle S Ludwig (1) · Paul Mathew, MD (1) · Repare Therapeutics (1) · University of Alabama at Birmingham (1) · University of Iowa (1)
United States (9) · France (2) · United Kingdom (2) · Greece (1) · South Korea (1) · Spain (1) · Taiwan (1)
Claudine Isaacs, MD (1) · Joseph Caster, MD, PhD (1) · Michelle S Ludwig, MD, MPH, PhD (1) · Paul Mathew, M.D. (1) · Rebecca Arend, MD (1) · Zofia Piotrowska, MD, MPH (1)
PMID 34904813, PMID 37651261, PMID 40705098
2018 (1)